• Judy Nee, Mohammed Zakari, and Anthony J Lembo.
• a Harvard Medical School, Beth Israel Deaconess Medical Center , Boston , MA , USA.
• Expert Opin Pharmacother. 2015 Jan 1; 16 (18): 2781-92.

IntroductionIrritable bowel syndrome diarrhea predominant (IBS-D) is a highly prevalent GI disease, affecting nearly a third of all patients diagnosed with irritable bowel syndrome. Current treatment options are limited.Areas CoveredThis review discusses the pharmacotherapeutic options for IBS-D including currently used medications, the two newly FDA approved medications, as well as emerging therapies with potential benefit in IBS-D. Particular emphasis is placed on rifaximin and eluxadoline and their possible use in IBS-D.Expert OpinionCurrent pharmacological treatment of IBS-D includes loperamide, bile acid sequestrants, antispasmodics, tricyclic antidepressants, alosetron, eluxadoline and rifaximin. The latter two treatments have significantly added to the pharmacotherapeutic options for patients suffering from IBS-D.

32 keywords...

hide…